Roberto Bianco

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

Fortunato Ciardiello, R. Caputo, Roberto Bianco et al. · PubMed · 2000 · 938 citations

Tumor Biology, Human Cancer Cells, Oncology +15

Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

Fortunato Ciardiello, Rosa Caputo, Roberto Bianco et al. · PubMed · 2001 · 644 citations

Chemoprevention Strategy, Human Growth, Pathology +17

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.

Stacy L. Moulder, F. Michael Yakes, Senthil K. Muthuswamy et al. · PubMed · 2001 · 548 citations

Breast Oncology, Medicine, Receptor Tyrosine Kinase +15

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

Roberto Bianco, Incheol Shin, Christoph A. Ritter et al. · Oncogene · 2003 · 452 citations

Medicine, Receptor Tyrosine Kinase, Pharmacology +5

Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.

Fortunato Ciardiello, Roberto Bianco, V. Damiano et al. · PubMed · 2000 · 380 citations

Tumor Biology, Oncology, Angiogenesis +13